Changes in the Penetration Rate of Biosimilar Infliximab Within Japan Using a Japanese Claims Database

PURPOSE: Infliximab, which was approved in 2002, had its first biosimilar launched in 2014 across Japan. However, the penetration rate of this biosimilar remains unclear given the limited data regarding its current clinical use throughout Japan. This study was conducted to describe the current clini...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsumoto, Tsugumi, Tsuchiya, Takanori, Hirano, Takahiro, Laurent, Thomas, Matsunaga, Kazuhisa, Takata, Jiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7920501/
https://www.ncbi.nlm.nih.gov/pubmed/33658813
http://dx.doi.org/10.2147/CEOR.S293698

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7920501/
https://www.ncbi.nlm.nih.gov/pubmed/33658813
http://dx.doi.org/10.2147/CEOR.S293698

Ejemplares similares